Top Page
Medmira
(MIR)
Medmira (MIR) vs. S&P 500 (SPY)
Medmira Business Overview & Revenue Model
Medmira Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 356.43K | 412.57K | 432.53K | 952.13K | 2.14M | 919.07K | Gross Profit |
| -204.56K | 226.49K | -434.91K | 304.03K | 1.72M | 572.28K | EBIT |
| -3.06M | -2.57M | -1.94M | -1.45M | -184.23K | -1.30M | EBITDA |
| -2.57M | -2.13M | -1.58M | -1.07M | 185.30K | -1.13M | Net Income Common Stockholders |
| -3.85M | -3.33M | -2.68M | -1.83M | -675.80K | -2.05M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.06M | 2.10M | 13.18K | 33.46K | -2.30M | 401.86K | Total Assets |
| 4.99M | 6.07M | 3.65M | 3.83M | 3.89M | 3.40M | Total Debt |
| 9.54M | 9.56M | 9.27M | 8.30M | 11.54M | 11.91M | Net Debt |
| 8.48M | 7.46M | 9.26M | 8.27M | 13.84M | 11.51M | Total Liabilities |
| 24.33M | 24.11M | 18.68M | 16.19M | 19.61M | 18.96M | Stockholders Equity |
| -19.34M | -18.04M | -15.03M | -12.36M | -15.72M | -15.56M |
| Cash Flow | Free Cash Flow | ||||
| -3.99M | -3.68M | -1.27M | -1.95M | -541.19K | -417.78K | Operating Cash Flow |
| -3.25M | -2.94M | -1.27M | -1.88M | -504.64K | -315.90K | Investing Cash Flow |
| -743.84K | -742.53K | -1.27K | -69.72K | -36.55K | -101.88K | Financing Cash Flow |
| 4.16M | 5.77M | 1.25M | 1.99M | 139.32K | 730.74K |
Medmira Technical Analysis
Medmira Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | C$61.42M | 12.15 | 19.57% | ― | 38.28% | ― | |
71 Outperform | C$362.16M | ― | -0.53% | 5.13% | -21.32% | 82.85% | |
59 Neutral | C$616.01M | ― | -3.84% | ― | 3.87% | -378.27% | |
52 Neutral | C$131.31M | ― | -23.20% | ― | -8.80% | 26.77% | |
49 Neutral | $6.94B | 0.38 | -53.52% | 2.46% | 20.13% | -0.66% | |
32 Underperform | C$83.41M | ― | ― | -17.04% | -34.15% |
Medmira Corporate Events
MedMira Inc. has announced a partnership with MediGroup, a major US healthcare group purchasing organization, to expand its market reach to over 44,000 healthcare providers. This collaboration will allow MedMira to offer its Reveal® G4 HIV rapid test, which is FDA approved and known for its quick and reliable results, to a broader audience, enhancing its industry positioning and providing significant growth opportunities.
MedMira Inc. has announced an exclusive distribution agreement with Trimedic Inc. to expand its presence in the Canadian market. This partnership follows the Health Canada approval of MedMira’s Multiplo® TP/HIV and Reveal® G4 HIV rapid tests, addressing the urgent need for reliable testing solutions amid rising STI cases in Canada. Trimedic’s established network and expertise in point-of-care diagnostics will support MedMira’s growth, particularly in underserved communities, enhancing access to essential testing devices.
MedMira Inc. has received Investigational Testing Authorizations from Health Canada to begin clinical trials for self-testing and non-professional use of its Multiplo® TP/HIV rapid test. This move is significant amid rising syphilis and HIV cases in Canada, especially in the Prairie regions, as it aims to provide accessible testing options for individuals who face barriers to healthcare. The trials, supported by the Canadian Institutes of Health Research, will be conducted by REACH Nexus at the MAP Centre for Urban Health Solutions. The tests are designed to offer quick, reliable results from a single finger-prick blood sample, potentially allowing users to confirm positive results through lab tests and access treatment promptly.
MedMira has received Health Canada approval for its Reveal® G4 Rapid HIV-1/2 Test for point-of-care use, marking a significant step in enhancing HIV detection in Canada. The test offers high sensitivity and specificity, delivering immediate results with minimal sample requirements, making it suitable for various healthcare settings, including underserved areas. This development aligns with Canada’s growing need for efficient HIV diagnostics, as recent data indicates a sharp increase in new HIV diagnoses. MedMira’s approval follows a previous approval of another rapid test, emphasizing the company’s commitment to expanding HIV screening options in the Canadian market.
MedMira Inc. has received investigational testing authorization from Health Canada to commence clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test. This innovative test, which offers a combined screening and confirmation process in under three minutes, represents a significant advancement in syphilis diagnostics. The clinical trials, funded by the Canadian Institute of Health Research and Indigenous Services Canada, will be conducted by REACH Nexus at the MAP Centre for Urban Health Solutions. The authorization is a critical step towards licensing the test in the Canadian market, addressing the urgent need for improved syphilis detection amid rising infection rates in Canada. The Multiplo® TP/nTP test promises to alleviate financial pressures on healthcare systems by providing a cost-effective and rapid diagnostic tool, enhancing the ability of healthcare providers to manage syphilis cases efficiently.
MedMira Inc. has reported significant progress in its regulatory and clinical activities, including Health Canada approval for its Multiplo® Rapid TP/HIV Test. The company anticipates higher-than-expected revenue growth in the Canadian market, driven by demand for its testing solutions and expansion efforts.
MedMira Inc. has received approval from Health Canada for its Multiplo Rapid TP/HIV Test, a crucial tool for addressing the health crises of HIV and syphilis in Canada. This rapid test, which provides immediate results using a simple finger prick, is expected to significantly impact the healthcare system by offering a fast and cost-effective screening method.